Fig. 3From: Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis resultsPercentage change from baseline in the sum of lesion diameters per investigator assessment (A) and IIR (B). aOne patient was assigned a BOR of “unknown” by IIR and was excluded from this analysis. BOR, best overall response; IIR, independent imaging review; PD, progressive disease; PR, partial response; SD, stable diseaseBack to article page